NDAORALSOLUTIONPriority Review
Approved
Nov 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
Chemokine Co-receptor 5 Antagonists
Pharmacologic Class:
CCR5 Co-receptor Antagonist
Clinical Trials (5)
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
Started Jun 2020
60 enrolled
COVID-19
Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Started Jun 2017
47 enrolled
HIV Infections
Maraviroc Efficacy for Hepatitis C
Started Jun 2017
10 enrolled
Hepatitis CHuman Immunodeficiency Virus
Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV
Started Mar 2017
90 enrolled
Hepatic SteatosisHIV-1-infection
Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial
Started Jan 2017
50 enrolled
Colorectal Cancer MetastaticPancreatic Cancer Metastatic